Yahoo Finance

Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool

SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics ...
Seeking Alpha

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...
The Globe and Mail

Recursion Pharmaceuticals Wants to 4X Its Supercomputing Power for AI With the Help of Nvidia. Here's Why It Matters.

For a biotech like Recursion Pharmaceuticals (NASDAQ: RXRX) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ...
CNBC

Lightning Round: Recursion Pharmaceuticals and NuScale Power

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more ...
Mena FN

Power Of Recursion OS On Display At Genome Scale In Nature Genetics Paper Detailing Potential Limitation Of CRISPR Gene Editing Tool

(MENAFN- GlobeNewsWire - Nasdaq) Published open-access today in Nature Genetics,“High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies ...